StockTipsArenaBeta

BUY Wockhardt Limited — Axis Securities

BUYWockhardt Limited
Wockhardt share price target & all analyst calls

byAxis SecuritiesHorizon: NA (inferred 1 year)8 Jul 2025via Institutional / Brokerage Research

Entry₹1,657.8Inferred
Target₹1,870
Total upside +12.80% (call closed)
Stop lossNot given
Exit₹1,87029 May 2026, 12:05 pm
Target hit+12.80%0.00%upside left
Follow Axis Securities for new calls(71% target hit, 810 closed calls)Get alertsWatch WOCKPHARMA for new buy/sell callsGet alertsSee 2 active Long-term calls on WOCKPHARMASee 184 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 8:44 am IST
2 supporting3 neutral0 opposing
Supports the BUY call (2)

Wockhardt's ZAYNICH® (Zidebactam/Cefepime) has received marketing authorization from the Indian drug regulator for treating complicated urinary tract infections.

NSE · Press Release·28 May · yesterday

(opens in new tab)

Wockhardt Limited reported positive Profit Before Tax (PBT) of Rs. 238 Cr for FY26, a significant turnaround from a loss of Rs. 16 Cr in the previous year. Revenue grew 11% to Rs. 3373 Cr, and EBITDA

NSE · Press Release·4 May · 3w ago

(opens in new tab)
Neutral / worth noting (3)

Wockhardt Limited's Board of Directors approved the audited financial results for the quarter and financial year ended March 31, 2026. They also approved a proposal for raising funds through various e

NSE · Outcome of Board Meeting·4 May · 3w ago

(opens in new tab)

Please be informed that the Board of Directors of the Company, at its meeting held today i.e. 4th May, 2026, inter-alia, has approved: i. the Audited Financial Results and Financial Statements ....

BSE · Board Meeting·4 May · 3w ago

(opens in new tab)

Wockhardt Limited's Board of Directors approved the Audited Financial Results for the quarter and financial year ended March 31, 2026. The board also approved a proposal for raising funds through vari

NSE · Outcome of Board Meeting·4 May · 3w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Wockhardt

All analyst calls on Wockhardt

More from Axis Securities

Every call and its outcome